PYC Therapeutics (ASX:PYC) has reported encouraging long-term data from its ongoing Phase 1/2 clinical program for VP-001, an investigational treatment targeting Retinitis Pigmentosa type 11.
PYC Therapeutics reports sustained vision gains in RP11 clinical trial
November 15, 2025 Australian Biotech
Latest Video
New Stories
-
It is profoundly wrong for any system to exclude compassion while outsourcing it to others
March 16, 2026 - - Latest News -
Scientists identify highly specific targets that could transform multiple myeloma treatment
March 15, 2026 - - Australian Biotech -
CSL Seqirus' adjuvanted flu vaccine approval extended to Australians aged 50 and over
March 15, 2026 - - Latest News -
GSK claims Pharma Cup as Kosi Challenge surpasses fundraising record
March 15, 2026 - - Latest News -
New program aims to make women’s health care more affordable and accessible
March 13, 2026 - - Latest News -
Australians turn to local pharmacies as frontline of everyday healthcare
March 13, 2026 - - Latest News -
Sandoz and Camp Quality unite to strengthen support for Australian families facing childhood cancer
March 13, 2026 - - Latest News

